<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>BMC Pulmonary Medicine - Latest articles</title>
		<link>http://www.biomedcentral.com/bmcpulmmed/</link>
		<description>The latest articles from BMC Pulmonary Medicine (ISSN 1471-2466) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/10"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/9"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/8"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/7"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/6"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/5"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/4"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/3"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/2"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/1"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/7/18"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/10">
            
            <title>Surfactant replacement and open lung concept - 
Comparison of two treatment strategies in an experimental model of neonatal ARDS
</title>
			<description>Background:
Several concepts of treatment in neonatal ARDS have been proposed in the last years. The present study compared the effects of open lung concept positive pressure ventilation (PPVOLC) with a conventional ventilation strategy combined with administration of two different surfactant preparations on lung function and surfactant homoeostasis.
Methods:
After repeated whole-lung saline lavage, 16 newborn piglets were assigned to either PPVOLC (n=5) or surfactant treatment under conventional PPV using a natural bovine (n=5) or a monomeric protein B based surfactant (n=6).
Results:
Comprehensive monitoring showed each treatment strategy to improve gas exchange and lung function, although the effect on PaO2 and pulmonary compliance declined over the study period in the surfactant groups. The overall improvement of the ventilation efficiency index (VEI) was significantly greater in the PPVOLC group. Phospholipid and protein analyses of the bronchoalveolar lavage fluid showed significant alterations to surfactant homoeostasis in the PPVOLC group, whereas IL-10 and SP-C mRNA expression was tendentially increased in the surfactant groups.
Conclusion:
The different treatment strategies applied could be shown to improve gas exchange and lung function in neonatal ARDS. To which extent differences in maintenance of lung function and surfactant homeostasis may lead to long-term consequences needs to be studied further.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/10</link>
			
			 	<dc:creator>Anne Hilgendorff, Ece Aslan, Thomas Schaible, Ludwig Gortner, Thorsten Baehner, Jochen Kreuder, Michael Ebsen, Clemens Ruppert, Andreas Guenther and Irwin Reiss</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:10</dc:source>
			<dc:date>2008-07-14</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-10</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>10</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-14</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/9">
            
            <title>Hypertonic saline reduces inflammation and enhances the resolution of oleic acid induced acute lung injury</title>
			<description>Background:
Hypertonic saline (HTS) reduces the severity of lung injury in ischemia-reperfusion, endotoxin-induced and ventilation-induced lung injury. However, the potential for HTS to modulate the resolution of lung injury is not known. We investigated the potential for hypertonic saline to modulate the evolution and resolution of oleic acid induced lung injury.
Methods:
Adult male Sprague Dawley rats were used in all experiments. Series 1 examined the potential for HTS to reduce the severity of evolving oleic acid (OA) induced acute lung injury. Following intravenous OA administration, animals were randomized to receive isotonic (Control, n = 12) or hypertonic saline (HTS, n = 12), and the extent of lung injury assessed after 6 hours. Series 2 examined the potential for HTS to enhance the resolution of oleic acid (OA) induced acute lung injury. Following intravenous OA administration, animals were randomized to receive isotonic (Control, n = 6) or hypertonic saline (HTS, n = 6), and the extent of lung injury assessed after 6 hours.
Results:
In Series I, HTS significantly reduced bronchoalveolar lavage (BAL) neutrophil count compared to Control [61.5 &#177; 9.08 versus 102.6 &#177; 11.89 &#215; 103 cells.ml-1]. However, there were no between group differences with regard to: A-a O2 gradient [11.9 &#177; 0.5 vs. 12.0 &#177; 0.5 KPa]; arterial PO2; static lung compliance, or histologic injury. In contrast, in Series 2, hypertonic saline significantly reduced histologic injury and reduced BAL neutrophil count [24.5 &#177; 5.9 versus 46.8 &#177; 4.4 &#215; 103 cells.ml-1], and interleukin-6 levels [681.9 &#177; 190.4 versus 1365.7 &#177; 246.8 pg.ml-1].
Conclusion:
These findings demonstrate, for the first time, the potential for HTS to reduce pulmonary inflammation and enhance the resolution of oleic acid induced lung injury.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/9</link>
			
			 	<dc:creator>Muiris T Kennedy, Brendan D Higgins, Joseph F Costello, William A Curtin and John G Laffey</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:9</dc:source>
			<dc:date>2008-07-08</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-9</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>9</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-08</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/8">
            
            <title>A cluster randomised controlled trial of nurse and GP partnership for care of Chronic Obstructive Pulmonary Disease</title>
			<description>Background:
Chronic obstructive pulmonary disease (COPD) is a significant health problem worldwide. This randomised controlled trial aims at testing a new approach that involves a registered nurse working in partnership with patients, general practitioners (GPs) and other health professionals to provide care to patients according to the evidence-based clinical practice guidelines. The aim is to determine the impact of this partnership on the quality of care and patient outcomes.
Methods:
A cluster randomised control trial design was chosen for this study. Randomisation occurred at practice level. GPs practising in South Western Sydney, Australia and their COPD patients were recruited for the study.The intervention was implemented by nurses specifically recruited and trained for this study. Nurses, working in partnership with GPs, developed care plans for patients based on the Australian COPDX guidelines. The aim was to optimise patient management, improve function, prevent deterioration and enhance patient knowledge and skills. Control group patients received 'usual' care from their GPs.Data collection includes patient demographic profiles and their co-morbidities. Spirometry is being performed to assess patients' COPD status and CO analyser to validate their smoking status. Patients' quality of life and overall health status are being measured by St George's Respiratory Questionnaire and SF-12 respectively. Other patient measures being recorded include health service use, immunisation status, and knowledge of COPD. Qualitative methods will be used to explore participants' satisfaction with the intervention and their opinion about the value of the partnership.AnalysisAnalysis will be by intention to treat. Intra-cluster (practice) correlation coefficients will be determined and published for all primary outcome variables to assist future research. The effect of the intervention on outcomes measured on a continuous scale will be estimated and tested using mixed model analysis of variance in which time and treatment group will be fixed effects and GP practice and subject nested within practice will be random effects. The effect of the intervention on the dichotomous variables (such as smoking status, patient knowledge) will be analysed using generalised estimating equations with a logistic link and a model structure that is analogous to that described above.Trial registrationACTRN012606000304538</description>
			<link>http://www.biomedcentral.com/1471-2466/8/8</link>
			
			 	<dc:creator>Nicholas Zwar, Oshana Hermiz, Iqbal Hasan, Elizabeth Comino, Sandy Middleton, Sanjyot Vagholkar and Guy Marks</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:8</dc:source>
			<dc:date>2008-06-03</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-8</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>8</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-03</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/7">
            
            <title>Do airway metallic stents for benign lesions confer too costly a benefit?</title>
			<description>Background:
The use of self-expanding metallic stents (SEMAS) in the treatment benign airway obstruction is controversial.
Methods:
To evaluate the safety and efficacy of SEMAS for this indication, we conducted a 10-year retrospective review at our tertiary medical centre.
Results:
Using flexible bronchoscopy, 82 SEMAS (67% Ultraflex, 33% Wallstent) were placed in 35 patients with inoperable lesions, many with significant medical comorbidities (88%). 68% of stents were tracheal, and 83% of patients showed immediate symptomatic improvement. Reversible complications developed in 9% of patients within 24 hrs of stent placement. Late complications (>24 hrs) occurred in 77% of patients, of which 37% were clinically significant or required an interventional procedure. These were mainly due to stent migration (12.2%), fracture (19.5%), or obstructive granulomas (24.4%). The overall granuloma rate of 57% was higher at tracheal sites (59%) than bronchial ones (34%), but not significantly different between Ultraflex and Wallstents. Nevertheless, Wallstents were associated with higher rates of bleeding (5% vs. 30%, p = 0.005) and migration (7% vs. 26%, p = 0.026). Of 10 SEMAS removed using flexible bronchoscopy, only one was associated with incomplete removal of fractured stent wire. Median survival was 3.6 &#177; 2.7 years.
Conclusion:
Ill patients with inoperable lesions may be considered for treatment with SEMAS.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/7</link>
			
			 	<dc:creator>Andrew L Chan, Maya M Juarez, Roblee P Allen and Timothy E Albertson</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:7</dc:source>
			<dc:date>2008-04-18</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-7</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>7</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-18</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/6">
            
            <title>Surfactant proteins SP-B and SP-C and their precursors in bronchoalveolar lavages from children with acute and chronic inflammatory airway disease</title>
			<description>Background:
The surfactant proteins B (SP-B) and C (SP-C) are important for the stability and function of the alveolar surfactant film. Their involvement and down-regulation in inflammatory processes has recently been proposed, but their level during neutrophilic human airway diseases are not yet known.
Methods:
We used 1D-electrophoresis and Western blotting to determine the concentrations and molecular forms of SP-B and SP-C in bronchoalveolar lavage (BAL) fluid of children with different inflammatory airway diseases. 21 children with cystic fibrosis, 15 with chronic bronchitis and 14 with pneumonia were included and compared to 14 healthy control children.
Results:
SP-B was detected in BAL of all 64 patients, whereas SP-C was found in BAL of all but 3 children; those three BAL fluids had more than 80% neutrophils, and in two patients, who were re-lavaged later, SP-C was then present and the neutrophil count was lower. SP-B was mainly present as a dimer, SP-C as a monomer. For both qualitative and quantitative measures of SP-C and SP-B, no significant differences were observed between the four evaluated patient groups.
Conclusion:
Concentration or molecular form of SP-B and SP-C is not altered in BAL of children with different acute and chronic inflammatory lung diseases. We conclude that there is no down-regulation of SP-B and SP-C at the protein level in inflammatory processes of neutrophilic airway disease.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/6</link>
			
			 	<dc:creator>Oliver Tafel, Philipp Latzin, Karl Paul, Tobias Winter, Markus Woischnik and Matthias Griese</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:6</dc:source>
			<dc:date>2008-04-11</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-6</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>6</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-11</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/5">
            
            <title>Assessing airway inflammation in clinical practice &#8211; experience with spontaneous sputum analysis</title>
			<description>Background:
The assessment of airway inflammation for the diagnosis of asthma or COPD is still uncommon in pneumology-specialized general practices. In this respect, the measurement of exhaled nitric oxide (NO), as a fast and simple methodology, is increasingly used. The indirect assessment of airway inflammation, however, does have its limits and therefore there will always be a need for methods enabling a direct evaluation of airway inflammatory cell composition. Sampling of spontaneous sputum is a well-known, simple, economic and non-invasive method to derive a qualitative cytology of airway cells and here we aimed to assess today's value of spontaneous sputum cytology in clinical practice.
Methods:
Three pneumologists provided final diagnoses in 481 patients having sputum cytology and we retrospectively determined posterior versus prior probabilities of inflammatory airway disorders. Moreover, in a prospective part comprising 108 patients, pneumologists rated their confidence in a given diagnosis before and after knowing sputum cytology and rated its impact on the diagnostic process on an analogue scale.
Results:
Among the 481 patients, 45% were diagnosed as having asthma and/or airway hyperresponsiveness. If patients showed sputum eosinophilia, the prevalence of this diagnosis was elevated to 73% (n = 109, p &lt; 0.001). The diagnosis of COPD increased from 40 to 66% in patients with neutrophilia (n = 29, p &lt; 0.01).Thirty-three of the 108 patients were excluded from the prospective part (26 insufficient samples, 7 incomplete questionnaires). In 48/75 cases the confidence into a diagnosis was raised after knowing sputum cytology, and in 15/75 cases the diagnosis was changed as cytology provided new clues.
Conclusion:
Our data suggest that spontaneous sputum cytology is capable of assisting in the diagnosis of inflammatory airway diseases in the outpatient setting. Despite the limitations by the semiquantitative assessment and lower sputum quality, the supportive power and the low economic effort needed can justify the use of this method, particularly if the diagnosis in question is thought to have an allergic background.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/5</link>
			
			 	<dc:creator>Olaf Holz, Tanja Seiler, Andreas Karmeier, Jan Fraedrich, Helmut Leiner, Helgo Magnussen, Rudolf A J&#246;rres and Lutz Welker</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:5</dc:source>
			<dc:date>2008-02-28</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-5</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>5</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-02-28</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/4">
            
            <title>Reproducibility of exhaled nitric oxide in smokers and non-smokers: relevance for longitudinal studies</title>
			<description>Background:
Currently, there is much interest in measuring fractional exhaled nitric oxide (FENO) in populations. We evaluated the reproducibility of FENO in healthy subjects and determined the number of subjects necessary to carry out a longitudinal survey of FENO in a population containing smokers and non-smokers, based on the assessed reproducibility.
Methods:
The reproducibility of FENO was examined in 18 healthy smokers and 21 non-smokers. FENO was assessed once at 9 AM on five consecutive days; in the last day this measurement was repeated at 2 PM. Respiratory symptoms and medical history were assessed by questionnaire. The within- and between-session repeatability of FENO and log-transformed FENO was described. The power of a longitudinal study based on a relative increase in FENO was estimated using a bilateral t-test of the log-transformed FENO using the between-session variance of the assay.
Results:
FENO measurements were highly reproducible throughout the study. FENO was significantly higher in males than females regardless of smoking status. FENO was positively associated with height (p &lt; 0.001), gender (p &lt; 0.034), smoking (p &lt; 0.0001) and percent FEV1/FVC (p &lt; 0.001) but not with age (p = 0.987). The between-session standard deviation was roughly constant on the log scale. Assuming the between-session standard deviation is equal to its longitudinal equivalent, either 111 or 29 subjects would be necessary to achieve an 80% power in detecting a 3% or a 10% increase in FENO respectively.
Conclusion:
The good reproducibility of FENO is not influenced by gender or smoking habits. In a well controlled, longitudinal study it should allow detecting even small increases in FENO with a reasonable population size.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/4</link>
			
			 	<dc:creator>Abraham Bohadana, Jean-Pierre Michaely, Dan Teculescu and Pascal Wild</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:4</dc:source>
			<dc:date>2008-02-28</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-4</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>4</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-02-28</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/3">
            
            <title>Influence of the incremental step size in work rate on exercise response and gas exchange in patients with pulmonary hypertension</title>
			<description>Background:
Cardiopulmonary exercise testing (CPET) has become increasingly important as a routine procedure in daily clinical work. So far, it is generally accepted that an individualized exercise protocol with exercise duration of 6 to 12 minutes is preferable to assess maximal exercise performance. The aim of this study was to compare an individualized NYHA adapted exercise protocol with a fixed standard protocol in patients with severe pulmonary arterial hypertension.
Methods:
Twenty-two patients (17 female, 5 male; mean age 49 &#177; 14 yrs) underwent symptom limited CPET on a bicycle. On two consecutive days each subject performed a stepwise CPET according to a modified Jones protocol (16 Watt per minute stages) as well as an individualized NYHA adapted protocol with 5 or 10 Watt/min stages in a randomized order. Oxygen uptake at peak exercise (peakVO2) and anaerobic threshold (VO2AT), maximal ventilation (VE), breathing reserve (VE/MVV), ventilatory efficiency (VE vs. VCO2 slope), exercise time, maximal power and work rate were assessed and compared between both protocols.
Results:
Comparing both, adapted NYHA protocol and standardized Jones protocol, we found significant differences in maximal power (56.7 &#177; 19 W vs. 74 &#177; 18 W; p &lt; 0.001) and exercise time (332 &#177; 107 sec. vs. 248 &#177; 72 sec.; p &lt; 0.001). In contrast, no significant differences were obvious comparing both protocols concerning work rate, VE, VE/MVV, peakVO2, VO2AT and VE vs. VCO2 slope.
Conclusion:
Variations of incremental step size during CPET significantly affect exercise time and maximal power, whereas relevant parameters for clinical judgement and prognosis such as oxygen uptake, ventilation and ventilatory efficiency remain unchanged. These findings have practical implications for the exercise evaluation of patients with pulmonary hypertension. To reach maximal results for ventilation, oxygen uptake and gas exchange an individualization of incremental step size appears not to be mandatory.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/3</link>
			
			 	<dc:creator>Sven Gl&#228;ser, Sven Lodziewski, Beate Koch, Christian F Opitz, Henry V&#246;lzke and Ralf Ewert</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:3</dc:source>
			<dc:date>2008-02-23</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-3</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>3</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-02-23</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/2">
            
            <title>Predictors of diagnostic yield in bronchoscopy: a retrospective cohort study comparing different combinations of sampling techniques</title>
			<description>Background:
The reported diagnostic yield from bronchoscopies in patients with lung cancer varies greatly. The optimal combination of sampling techniques has not been finally established.The objectives of this study were to find the predictors of diagnostic yield in bronchoscopy and to evaluate different combinations of sampling techniques.
Methods:
All bronchoscopies performed on suspicion of lung malignancy in 2003 and 2004 were reviewed, and 363 patients with proven malignant lung disease were included in the study. Sampling techniques performed were biopsy, transbronchial needle aspiration (TBNA), brushing, small volume lavage (SVL), and aspiration of fluid from the entire procedure. Logistic regression analyses were adjusted for sex, age, endobronchial visibility, localization (lobe), distance from carina, and tumor size.
Results:
The adjusted odds ratios (OR) with 95% confidence intervals (CI) for a positive diagnostic yield through all procedures were 17.0 (8.5&#8211;34.0) for endobronchial lesions, and 2.6 (1.3&#8211;5.2) for constriction/compression, compared to non-visible lesions; 3.8 (1.3&#8211;10.7) for lesions > 4 cm, 6.7 (2.1&#8211;21.8) for lesions 3&#8211;4 cm, and 2.5 (0.8&#8211;7.9) for lesions 2&#8211;3 cm compared with lesions &lt;= 2 cm. The combined diagnostic yield of biopsy and TBNA was 83.7% for endobronchial lesions and 54.2% for the combined group without visible lesions. This was superior to either technique alone, whereas additional brushing, SVL, and aspiration did not significantly increase the diagnostic yield.
Conclusion:
In patients with malignant lung disease, visible lesions and larger tumor size were significant predictors of higher diagnostic yield, after adjustment for sex, age, distance from carina, side and lobe. The combined diagnostic yield of biopsy and TBNA was significant higher than with either technique alone.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/2</link>
			
			 	<dc:creator>Kjetil Roth, Jon A Hardie, Alf H Andreassen, Friedemann Leh and Tomas ML Eagan</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:2</dc:source>
			<dc:date>2008-01-26</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-2</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>2</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-01-26</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/1">
            
            <title>Effect of a 14-day course of systemic corticosteroids on the hypothalamic-pituitary-adrenal-axis in patients with acute exacerbation of chronic obstructive pulmonary disease</title>
			<description>Background:
As supra-physiological intake of corticosteroids is a well known risk factor for the development of adrenal insufficiency, we investigated the function of the hypothalamic-pituitary-adrenal (HPA) axis during a 14-day course of systemic corticosteroids in patients with acute exacerbation of chronic obstructive pulmonary disease using clinical and laboratory measures.
Methods:
A systematic clinical and laboratory assessment including measurement of basal cortisol levels and the response to low dose (1 &#956;g) ACTH stimulation was performed in nine patients before, on the first and the last day of treatment, as well as 2, 7 and 21 days after corticosteroid withdrawal.
Results:
At baseline, all nine patients had normal responses to 1 &#956;g ACTH. On the first day of steroid treatment, 78% had a blunted peak cortisol response. This percentage increased to 89% after 14 days of steroid treatment. 78%, 33% and 33% of the patients had a blunted cortisol response to ACTH 2, 7, and 21 days after corticosteroid withdrawal, respectively. ROC curve analysis revealed that only basal cortisol concentrations (AUC 0.89), but not ACTH concentrations (AUC 0.49) or clinical signs (AUC 0.47) were predictive of an impaired function of the HPA axis. Basal cortisol levels of > 400 and &lt; 150 nmol/l were 96% and 100% sensitive for a normal or pathological response to the ACTH stimulation test, respectively.
Conclusion:
Immediate and prolonged suppression of the HPA axis is a common finding in otherwise asymptomatic patients undergoing systemic steroid treatment for acute exacerbation of chronic obstructive pulmonary disease and can reliably be assessed with the low-dose ACTH test.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/1</link>
			
			 	<dc:creator>Philipp Schuetz, Mirjam Christ-Crain, Ursula Schild, Erika S&#252;ess, Michael Facompre, Florent Baty, Charly Nusbaumer, Martin Brutsche and Beat M&#252;ller</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:1</dc:source>
			<dc:date>2008-01-26</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-1</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>1</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-01-26</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/7/18">
            
            <title>Assessment of the alveolar volume when sampling exhaled gas at different expired volumes in the single breath diffusion test</title>
			<description>Background:
Alveolar volume measured according to the American Thoracic Society-European Respiratory Society (ATS-ERS) guidelines during the single breath diffusion test can be underestimated when there is maldistribution of ventilation. Therefore, the alveolar volume calculated by taking into account the ATS-ERS guidelines was compared to the alveolar volume measured from sequentiallly collected samples of the expired volume in two groups of individuals: COPD patients and healthy individuals. The aim of this study was to investigate the effects of the maldistribution of ventilation on the real estimate of alveolar volume and to evaluate some indicators suggestive of the presence of maldistribution of ventilation.
Methods:
Thirty healthy individuals and fifty patients with moderate-severe COPD were studied. The alveolar volume was measured either according to the ATS-ERS guidelines or considering the whole expired volume subdivided into five quintiles. An index reflecting the non-uniformity of the distribution of ventilation was then derived (DeltaVA/VE).
Results:
Significant differences were found when comparing the two measurements and the alveolar volume by quintiles appeared to have increased progressively towards residual volume in healthy individuals and much more in COPD patients. Therefore, DeltaVA/VE resulted in an abnormal increase in COPD.
Conclusion:
The results of our study suggest that the alveolar volume during the single breath diffusion test should be measured through the collection of a sample of expired volume which could be more representative of the overall gas composition, especially in the presence of uneven distribution of ventilation. Further studies aimed at clarifying the final effects of this way of calculating the alveolar volume on the measure of DLCO are needed. DeltaVA/VE is an index that can help assess the severity of inhomogeneity in COPD patients.</description>
			<link>http://www.biomedcentral.com/1471-2466/7/18</link>
			
			 	<dc:creator>Renato Prediletto, Edo Fornai, Giosu&#232; Catapano and Cristina Carli</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2007, 7:18</dc:source>
			<dc:date>2007-12-19</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-7-18</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>18</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-12-19</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
